Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | ABL1 | P00519 | 12/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.75 |
| ▸ | CSK | P41240 | 1/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.74 |
| ▸ | PRKDC | P78527 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574791 | 1.00 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL17963679 | 0.93 | SRC (0.86) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29390308 | 0.91 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL14574566 | 0.91 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL12436444 | 0.90 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL14574731 | 0.90 | SRC (0.82) | SRCABL1HCKEGFRPIK3CD | |
| SCHEMBL12436046 | 0.90 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL14574643 | 0.89 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29389641 | 0.89 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29389616 | 0.88 | SRC (1.00) | SRCABL1HCKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885HCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.